An interventional study of Prehabilitation Programming in Cirrhosis, Liver, Liver Transplant Surgery and Liver Disease, sponsored by University of Alberta. Active, not recruiting at 6 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of Alberta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Liver Cirrhosis with a site in Canada — 7 open to participants now, 11 under way, 2 of them phase 3. Liver Cirrhosis · Canada.
Among the 46 studies in Liver Cirrhosis with a site in Canada, this one is the 17th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 38th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →7 of the 46 studies in Liver Cirrhosis with a site in Canada are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Canada, United States
Ages 18–75
Boehringer Ingelheim · Sites in Canada, United States, Argentina and 34 more countries
Ages 18+
The Cleveland Clinic · Sites in Canada, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
European Foundation for Study of Chronic Liver Failure · Sites in Canada, United States, Argentina and 24 more countries
Ages 18–80
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 179 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 151 across the 35 interventional studies, 401 across the 10 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 46 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
University of Alberta has 4 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Liver Cirrhosis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07885007University Health Network, TorontoAI-SC Multi-center Study | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07325526Boehringer IngelheimA Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | 2027-08-05 |
| NCT07927153University Health Network, TorontoProspective AI-SC Trial | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Liver Cirrhosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Physical frailty is common in patients awaiting liver transplantation and has been associated with poor health outcomes. There is promising data from small studies showing that behavioural, nutrition, exercise therapy (prehabilitation) improves physical function in patients while they are waiting for a liver transplant.
The proposed trial will assess if a 12-week online prehabilitation program improves physical function in patients listed for liver transplantation. Over 4 years, 177 patients will be recruited from 6 transplant centres across Canada and will be randomized to receive either the online prehabilitation program or usual care.
The primary outcome of physical function will be evaluated using the FTSST at baseline and 12 weeks (or last timepoint before transplant) assessed virtually or in-person. Secondary outcomes include liver specific physical frailty, aerobic fitness, health-related quality of life (QoL), participant experience and acceptability. Exploratory outcomes include other virtual and in-person physical function measures, covert hepatic encephalopathy (CHE), sarcopenia, malnutrition, adherence, behaviour factors, clinical and post-transplant outcomes. Results will be compared between the intervention and usual care groups.
This multi-centre randomized controlled trial (RCT) will be completed across the six major LT programs in Canada: Vancouver, Edmonton, Calgary, Toronto, London, and Montreal.
Participants involved in this study will be LT transplant candidates with cirrhosis who are receiving care at one of the six participating LT programs.
Participants will be assessed for eligibility, provided informed signed consent, complete baseline testing and then be randomized to the prehabilitation arm or usual care. Participants will be randomized in a 2:1 ratio between groups.
Prehabilitation Arm:
The 12 week prehabilitation program includes exercise, nutrition and psychological components that is accessed through the online digital web platform.
Control/Usual Care Arm:
This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform. A short questionnaire will be sent to control participants every 4 weeks to track changes in physical activity.
Post-Transplant follow-up In the subgroup of patients who undergo LT, the same in-person and virtual testing will be carried out at 12 weeks post-transplant (timing may vary due to site clinic flow)
Data Collection Plan
Sample size calculations are based on the primary outcome (the chair stand test: time to complete 5 sit-to-stands) using individual data from our local exercise study in cirrhosis (n=59), plus our sit-to-stand data from our study of 694 patients. After accounting for lack of trial completion, loss to follow up, the total sample size is 177, with 59 participants in the control and 118 in the intervention arm.
Types of analyses
Primary outcome: The primary outcome (sit to stand test; time to do 5 sit-to-stands) will be analyzed by linear mixed models with random effects, adjusted for baseline score as a covariate. Sites will be entered as random effects.
Secondary/exploratory outcomes: (1) Quantitative outcomes: Similar types of models will be used for continuous secondary/exploratory outcomes. To examine predictors of exercise and nutrition adherence (e.g. COM-B results), generalized linear models with binary outcome will be employed. To evaluate the potential effect of selected demographic variables on outcomes, as an exploratory analysis, models will be adjusted for clinically significant variables (e.g. sex, gender, digital technology proficiency). Results will be primarily descriptive. Exploratory per-protocol analysis will be performed, and the results will be presented if substantial differences are found between this group and the intention-to-treat group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥18 years old with cirrhosis (confirmed with transient elastography by FibroScan, histology, or imaging-based assessment with compatible clinical picture), referred for transplant and are assessed to have a high likelihood of being listed according to a preliminary review by hepatologist or are already listed for LT, are pre-frail or frail on the liver frailty index (LFI) or (added August 30, 2024) pre-frail or frail on the TeLeFI (prefrail LFI 3.2-4.3 and frail LFI ≥4.4), have English or French language proficiency, and own an internet-connected device.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The prehabilitation group will be provided with access to the online digital web platform which contains the weekly acceptance and commitment therapy based education videos, nutrition intervention, and exercise intervention.
Behavioral: Prehabilitation Programming
This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform.
12-weeks of online prehabilitation programming including: 1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk. 2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos). 3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence.
Change in time to do 5-sit-to-stands from baseline
A time to complete 5 chair stands of \>15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform
Time frame: Week 0
Change in time to do 5-sit-to-stands from baseline
A time to complete 5 chair stands of \>15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform
Time frame: Week 12
Change in liver frailty index from baseline
Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization. The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index \< 3.2, robust; 3.2-4.5, prefrail; and \>4.5, frail). Higher scores mean a worse outcome.
Time frame: Week 0
Change in liver frailty index from baseline
Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization. The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index \< 3.2, robust; 3.2-4.5, prefrail; and \>4.5, frail). Higher scores mean a worse outcome.
Time frame: Week 12
Changes in virtual physical function testing over time (2-min step test)
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Week 0
Changes in virtual physical function testing over time (2-min step test)
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Week 12
Change in health-related quality of life from baseline (CLDQ)
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.
Time frame: Week 0
Change in health-related quality of life from baseline (CLDQ)
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.
Time frame: Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
Time frame: Week 0
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
Time frame: Week 12
Qualitative Acceptability Data
Inductive analysis of post-trial semi-structured interviews/focus groups with participants
Time frame: Week 12
Change in time to do 5-sit-to-stands from baseline
A time to complete 5 chair stands of \>15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform Completed at week 8 to account for the possibility of transplantation or loss-to-follow-up before the end of the 12 weeks.
Time frame: Week 8
Change in sarcopenia from baseline
Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia
Time frame: Week 0
Change in sarcopenia from baseline
Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia
Time frame: Week 12
Change in distance in the 6 minute walk test from baseline
6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.
Time frame: Week 0
Change in distance in the 6 minute walk test from baseline
6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.
Time frame: Week 12
Change in covert hepatic encephalopathy from baseline
The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.
Time frame: Week 0
Change in covert hepatic encephalopathy from baseline
The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.
Time frame: Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
Time frame: Week 8
Change in health-related quality of life from baseline (CLDQ)
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.
Time frame: Week 8
Change in 6-item COM-B scale over time during intervention
Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 \[strongly disagree\] to 7 \[strongly agree\]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation
Time frame: Week 4
Change in 6-item COM-B scale over time during intervention
Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 \[strongly disagree\] to 7 \[strongly agree\]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation
Time frame: Week 8
Change in 6-item COM-B scale over time during intervention
Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 \[strongly disagree\] to 7 \[strongly agree\]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation.
Time frame: Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
Time frame: Post-transplant (12 weeks after transplant date)
Change in health-related quality of life from baseline (CLDQ)
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.
Time frame: Post-transplant (12 weeks after transplant date)
Changes in virtual physical function testing over time (Single leg balance test)
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Week 0
Changes in virtual physical function testing over time (Single leg balance test)
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Week 8
Changes in virtual physical function testing over time (Single leg balance test)
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Week 12
Changes in virtual physical function testing over time (Single leg balance test)
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Post-transplant (12 weeks after transplant date)
Changes in virtual physical function testing over time (2-min step test)
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Week 8
Changes in virtual physical function testing over time (2-min step test)
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing
Time frame: Post-transplant (12 weeks after transplant date)
Number of participants who died during the 12 week trial
Death will be collected through chart review
Time frame: Week 12
Number of hospitalizations and ambulatory clinic visits during the 12 week trial
Hospitalizations and ambulatory clinic visits will be collected through chart review
Time frame: Week 12
Number of participants who were transplanted during the 12 week trial
Data on transplantations occurring during the trial will be collected through chart review
Time frame: Week 12
Number of participants who died during the 2 years post-study completion
Death will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.
Time frame: 2 years post-study completion
Number of hospitalizations and ambulatory clinic visits during the 2 years post-study completion
Hospitalizations and ambulatory clinic visits will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.
Time frame: 2 years post-study completion
Number of participants who were transplanted during the 2 years post-study completion
Data on transplantations occurring during the trial will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.
Time frame: 2 years post-study completion
Economic Evaluation
Healthcare access and hospital usage will be collected through patient survey.
Time frame: Week 12
Total Length of stay at time of transplant
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain total length of stay at time of transplant
Time frame: Post-transplant up to 3 months of the trial data collection period
Intensive care unit length of stay at time of post transplant
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain intensive care unit length of stay
Time frame: Post-transplant up to 3 months of the trial data collection period
Days of mechanical ventilation at time of post transplant
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain days of mechanical ventilation
Time frame: Post-transplant up to 3 months of the trial data collection period
Discharge location from hospital at time of transplant
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain discharge home from hospital (versus rehabilitation, nursing home or other institutional location)
Time frame: Post-transplant up to 3 months of the trial data collection period
Readmissions within 30 days at time of transplant
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain any readmissions within 30 days.
Time frame: Post-transplant up to 3 months of the trial data collection period
Malnutrition
The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes. The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).
Time frame: Week 0
Malnutrition
The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes. The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).
Time frame: Week 12
Adverse events
Major: death or hospitalization for an event occurring during or up to 3 h after exercise; cardiovascular events (stroke, myocardial infarction); permanent disability; angina, syncope, arrhythmia; variceal bleeding. Minor: hypoglycemia, hyper- or hypotension requiring medical attention, musculoskeletal injury or fall.
Time frame: Week 12
Changes in health care provider support from baseline
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.
Time frame: Week 0
Changes in physical activity levels from baseline
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.
Time frame: Week 0
Changes in health care provider support from baseline
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.
Time frame: Week 4
Changes in physical activity levels from baseline
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.
Time frame: Week 4
Changes in health care provider support from baseline
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.
Time frame: Week 8
Changes in physical activity levels from baseline
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.
Time frame: Week 8
Changes in health care provider support from baseline
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.
Time frame: Week 12
Changes in physical activity levels from baseline
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.
Time frame: Week 12
Changes in functional status from baseline
The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI
Time frame: Week 0
Changes in functional status from baseline
The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI
Time frame: Week 8
Changes in functional status from baseline
The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI
Time frame: Week 12
Adherence to prehabilitation program goals
(i) 70% adherence to target protein intake and protein powder supplementation (assessed by dietary intake, nutrition check ins, platform metrics and monthly nutrition questionnaires), (ii) 70% adherence to exercise sessions (assessed by attendance, check ins, platform metrics) excluding study weeks with interruptions to programming due to health related issues (e.g. transplant dry runs, hospital admissions as these are common in patients awaiting LT)
Time frame: Week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Aug 2026, 37 months.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's 37 months is close to that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.